Managing hematologic toxicities in the oncology patient

Journal of Infusion Nursing

Volumn 30, Issue 3, 2007, Pages 168-172

  Montoya, Libby ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Mail Stop 120 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; BUSULFAN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TIOGUANINE; TOPOTECAN; UNINDEXED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAREGIVER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEHYDRATION; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; ECONOMIC EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; HEALTH ECONOMICS; HOSPITAL CHARGE; HUMAN; INFECTION; INTERMETHOD COMPARISON; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NURSING CARE; PATIENT CARE; PATIENT EDUCATION; PATIENT INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; BONE MARROW; DRUG MONITORING; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT CARE TEAM; PATIENT EDUCATION; SAFETY MANAGEMENT;

EID: 34249012511     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000270676.59180.c3     Document Type: Review

References (28)

1. Waladkhani A-R. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia. Eur J Cancer Care. 2004;13(4):371-379.
2. Cappozzo C. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia. Oncol Nurs Forum. 2004;31(3):569-574.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: fever and neutropenia. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/fever.pdf. Accessed August 24, 2006.
4. Donohue RB. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncol Nurs Forum. 2006;33(2):347-352.
5. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-340.
6. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164-170.
7. Feld R. Multinational cooperation in trials and guidelines dealing with febrile neutropenia. Int J Antimicrob Agents. 2000;16(2):185-187.
8. Eggenberger SK, Krumwiede N, Meiers SJ, et al. Family caring strategies in neutropenia. Clin J Oncol Nurs. 2004;8(6):617-621.
9. Moore K, Crom D. Hematopoietic support with moderately myelosuppressive chemotherapy regimens: a nursing perspective. Clin J Oncol Nurs. 2006;10(3):383-388.
10. Welte K, Gabrilove J, Bronchurd MH, et al. Filgrastim (r-metHuGCSF): the first 10 years. Blood. 1996;88(6):1907-1929.
11. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164-170.
12. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocytecolony stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-411.
13. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27(12):1724-1729.
14. Green MD, Koelbl H, Baselga J, et al. A randomized double-blinded study of fixed dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29-35.
15. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34(12):1857-1864.
16. Foubert J. Cancer-related anaemia and fatigue: assessment and treatment. Nurs Stand. 2006;20(36):50-57.
17. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-2306.
18. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689-1692.
19. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616-1634.
20. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumors. Med Oncol. 1998;15(Suppl 1):S19-S28.
21. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2): 13-19.
22. Vogelzang NJ, Breithart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34(3 Suppl 2):4-12.
23. Barrett-Lee PJ, Bailey NP, O'Brien MER, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82(1):93-97.
24. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002;20(10):2486-2494.
25. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865-2874.
26. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211-1220.
27. Buyukpamukcu M, Varan A, Kutluk T, et al. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Pediatr Hematol Oncol. 2002;21(4):455-458.
28. Razzouk, BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24(22):3583-3589.